Loading...
•
Jun 30, 2022
Alkermes Q2 2022 Earnings Report
Reported financial results for the second quarter of 2022 and provided updated financial expectations for full-year 2022.
Key Takeaways
Alkermes reported Q2 2022 financial results with total revenues of $276.2 million. Net sales of proprietary products were $190.8 million, driven by VIVITROL, ARISTADA, and LYBALVI. The company raised its financial expectations for full-year 2022.
Total revenues for the quarter were $276.2 million.
Net sales of proprietary products for the quarter were $190.8 million.
Net loss according to GAAP was $30.1 million for the quarter, or a basic and diluted GAAP loss per share of $0.18.
Non-GAAP net income was $10.5 million for the quarter, or a non-GAAP basic and diluted earnings per share of $0.06.
Alkermes
Alkermes
Alkermes Revenue by Segment
Revenue by Segment
VIVITROL Revenue
CapyFin.comARISTADA Revenue
CapyFin.comLYBALVI Revenue
CapyFin.com Forward Guidance
The following updated financial expectations for 2022 primarily reflect LYBALVI’s launch performance to date and the company’s current assumption that it will continue to receive royalty payments related to sales of the long-acting INVEGA products outside the U.S. through at least October 2022.
Positive Outlook
- Total Revenue: $1,050 - $1,120 million
- VIVITROL Net Sales: $365 - $385 million
- ARISTADA Net Sales: $295 - $315 million
- LYBALVI Net Sales: $75 - $90 million
- INVEGA Franchise Royalties: $95 - $100 million
Challenges Ahead
- Cost of Goods Sold: $215 - $225 million
- R&D Expenses: $380 - $400 million
- SG&A Expenses: $575 - $605 million
- GAAP Net Loss: ($145) - ($175) million
- GAAP Net Loss per Share: ($0.88) - ($1.07)
Revenue & Expenses
Visualization of income flow from segment revenue to net income